Peripheral arterial disease (PAD) is a major risk marker for systemic ischaemic events. The understanding of PAD has moved from PAD as an organ-specific disease to PAD as the lower-limb localization of a multifocal disease, i.e. atherothrombosis. Blood platelet activation and aggregation is a common denominator in atherothrombotic events, and use of antiplatelet agents in patients with PAD can inhibit thrombus formation and reduce the occurrence of myocardial infarction (MI), ischaemic stroke (IS) and vascular death. Many studies have investigated various antiplatelet regimens for preventing acute cardiovascular events in patients with a prior ischaemic event, although many of these studies had a number of limitations. The Antiplatelet Trialists' Collaboration performed a meta-analysis of 23 stroke trials and found an average odds risk reduction of 25% for a combined endpoint of stroke, MI or vascular death. The concept of atherothrombosis as a multifocal disease was challenged by the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial. This study showed an 8.7% decrease in the relative risk reduction for further atherothrombotic events with clopidogrel over aspirin (p = 0.043) for the overall population, in terms of the combined endpoint of IS, MI or vascular death.
Introduction
Peripheral arterial disease (PAD) is a major risk marker for ischaemic events, including myocardial infarction (MI) and ischaemic stroke (IS). 1 PAD is the lower-limb localization of a multifocal clinical condition, i.e. atherosclerosis. Patients with PAD may be asymptomatic or have atypical symptoms, such that the disease is often unrecognized. But even if the disease is recognized, physicians may not appreciate that PAD is a strong marker for coronary artery disease (CAD) and cerebrovascular disease (CBVD). 2 Consequently, PAD is under-treated, which has serious implications because untreated PAD may lead to ischaemic rest pain, gangrene, or the need for amputation in 3-8% of affected individuals per year. 3 Moreover, the 10-year mortality rate for PAD patients is 40-50%, mostly due to CAD or CBVD. 4 to an active form with high affinity for fibrinogen. The active receptor binds fibrinogen, which in turn binds to another platelet, thus initiating thrombus formation and potentially leading to peripheral arterial occlusion, MI and IS.
Atherosclerosis is a generalized disease and patients with atherothrombotic disease in one vascular bed are at risk of an ischaemic event in another vascular bed. 7-10 The pathological overlap of CAD, PAD and CBVD is discussed in more detail elsewhere in this supplement. 11
Clinical trials of platelet aggregation inhibitors
Earlier studies performed in the 1960s, 1970s and 1980s had a number of limitations: too small a sample size, undefined study population, and poorly defined endpoints. Furthermore, many of the agents tested had a suboptimal efficacy.
The meta-analysis of randomized trials conducted in patients with a prior ischaemic event by the Antiplatelet Trialists' Collaboration (ATC) 12 proved the concept of atherothrombosis as a multifocal disease. A total of 145 trials, including patients at risk of ischaemic events and treated with different antiplatelet regimens, were analysed. The combined ischaemic endpoint used was stroke, MI and vascular death, and the average odds reduction produced by antiplatelet therapy (mainly aspirin) was 25% compared with controls.
The concept of atherothrombosis as a multifocal disease was prospectively validated by the CAPRIE trial, 13 which included patients with various ischaemic manifestations of cerebrovascular, cardiac and peripheral arterial disease within a single protocol. The trial recruited 19 185 patients, who were followed for 1-3 years (mean 1.91 years). The efficacy of clopidogrel (75 mg daily) was compared with aspirin (325 mg daily) for a combined endpoint of IS, MI or vascular death. There was an 8.7% overall relative risk reduction for further atherothrombotic events with clopidogrel over aspirin (p = 0.043) in addition to the 25% odds reduction historically observed with aspirin versus placebo in the ATC meta-analysis.
Pharmacological agents and regimens
Aspirin, ticlopidine and dipyridamole have limitations in efficacy and safety. Vascular events occur despite the use of aspirin, and up to one-third of patients may not respond to aspirin. 14 Aspirin also causes gastrointestinal haemorrhage and intracerebral haemorrhage in a small number of cases, and it may not be tolerated because of allergy. [15] [16] [17] [18] Ticlopidine is occasionally associated with neutropenia and aplastic anaemia: neutropenia occurred in 2.4% of cases and severe neutropenia in 0.9% of patients 19, 20 ; other nonfatal adverse events include diarrhoea in Ն20% of cases and rash (11%). 20 Dipyridamole has not shown a therapeutic benefit over that produced by aspirin alone. 17, [21] [22] [23] [24] Data from the second European Stroke Prevention Study (ESPS-2), 17 suggesting that the combination of very-lowdose aspirin with high-dose dipyridamole offers additional benefit over aspirin alone for the prevention of stroke, are only partially supported by previous trials of this combination of antiplatelet agents and failed to demonstrate any benefit for MI or mortality.
The ADP-receptor antagonist clopidogrel offers safety advantages over aspirin and ticlopidine. 6, 25 Clopidogrel has better gastric tolerability than aspirin, although diarrhoea, rash and pruritus occur more frequently with clopidogrel than with aspirin treatment. The use of clopidogrel with aspirin appears promising because of the potential synergism between the two drugs, 26, 27 and this approach was recently investigated in the Clopidogrel in Unstable angina to prevent Recurrent ischaemic Events (CURE) trial. 28 The results, which were presented at the 50th Annual Scientific Session of the American College of Cardiology 29 clearly showed that the use of clopidogrel with aspirin was more effective than aspirin alone in reducing cardiovascular events in patients with unstable angina or non-Q-wave MI.
Specific GP IIb/IIIa antagonists have been studied in acute coronary syndromes and percutaneous coronary intervention. Although intravenous use of these agents has shown clinical benefit, oral formulations have not proved superior to aspirin based on data from five large clinical trials with xemilofiban (EXCITE), 30 orbofiban (OPUS), 31 sibrafiban (SYMPHONY I and II) 32, 33 and lotrafiban (BRAVO). 34, 35 
Conclusions and future perspectives
Educational programmes for physicians are needed, along with suitable patient screening programmes. Patient compliance with risk factor modifications and pharmacological treatment regimens need to be improved. An educational programme for general practitioners could have a number Vascular Medicine 2001; 6 (suppl 1): [13] [14] [15] of objectives. A key aim would be to improve the awareness of the concept of PAD as a multifocal, instead of an organ-specific, disease -one of only several manifestations of atherothrombosis.
New, non-invasive diagnostic procedures for PAD should help to facilitate an understanding of the epidemiology of PAD, in both symptomatic and non-symptomatic patients. Groups at high risk for PAD and CBVD can be identified, screened and targeted for intervention, thus helping to optimize current treatments. In order to reduce and prevent atherothrombotic morbidity and mortality, new pharmacological agents and regimens, such as combination antiplatelet therapy, need to be investigated.
